Witnessing the stock’s movement on the chart, on Thursday, Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) had a quiet start as it plunged -4.82% to $3.95, before settling in for the price of $4.15 at the close. Taking a more long-term approach, IRWD posted a 52-week range of $3.79-$15.70.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare sector firm’s twelve-monthly sales growth has been 5.56% for the last half of the decade. Meanwhile, its Annual Earning per share during the time was -28.37%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 103.08%. This publicly-traded company’s shares outstanding now amounts to $156.35 million, simultaneously with a float of $155.59 million. The organization now has a market capitalization sitting at $630.97 million. At the time of writing, stock’s 50-day Moving Average stood at $4.36, while the 200-day Moving Average is $7.45.
Ironwood Pharmaceuticals Inc (IRWD) Ownership Facts and Figures
Nothing is more important than checking the behaviour of major investors towards the stock of the Drug Manufacturers – Specialty & Generic industry. Ironwood Pharmaceuticals Inc’s current insider ownership accounts for 2.60%, in contrast to 107.77% institutional ownership. According to the most recent insider trade that took place on Aug 12 ’24, this organization’s Chief Legal Officer sold 9,910 shares at the rate of 4.27, making the entire transaction reach 42,316 in total value, affecting insider ownership by 284,661. Preceding that transaction, on Aug 12 ’24, Company’s Principal Accounting Officer sold 3,107 for 4.27, making the whole transaction’s value amount to 13,267. This particular insider is now the holder of 158,370 in total.
Ironwood Pharmaceuticals Inc (IRWD) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.11 per share during the current fiscal year.
Ironwood Pharmaceuticals Inc’s EPS increase for this current 12-month fiscal period is 103.08% and is forecasted to reach 0.34 in the upcoming year.
Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) Trading Performance Indicators
Let’s observe the current performance indicators for Ironwood Pharmaceuticals Inc (IRWD). It’s Quick Ratio in the last reported quarter now stands at 3.92. The Stock has managed to achieve an average true range (ATR) of 0.24. Alongside those numbers, its PE Ratio stands at $91.44, and its Beta score is 0.47. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 1.58. Similarly, its price to free cash flow for trailing twelve months is now 4.31.
In the same vein, IRWD’s Diluted EPS (Earnings per Share) trailing twelve months is recorded 0.04, a figure that is expected to reach 0.07 in the next quarter, and analysts are predicting that it will be 0.34 at the market close of one year from today.
Technical Analysis of Ironwood Pharmaceuticals Inc (IRWD)
Going through the that latest performance of [Ironwood Pharmaceuticals Inc, IRWD]. Its last 5-days volume of 1.28 million was inferior to the volume of 2.98 million it revealed a year ago. During the previous 9 days, stock’s Stochastic %D was recorded 34.55% While, its Average True Range was 0.24.
Raw Stochastic average of Ironwood Pharmaceuticals Inc (IRWD) in the period of the previous 100 days is set at 4.83%, which indicates a major fall in contrast to 8.15% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 43.46% that was lower than 85.75% volatility it exhibited in the past 100-days period.
